Judy Bebchuk, Sc.D. Senior Biostatistician

View Biography Print this Section

Pace C, Grady C, Wendler D, Bebchuk J, Tavel J, McNay L, Forster H, Killen J, Emanuel E for the ESPIRIT Group. Post trial access to tested interventions: The views of IRB/REC Chairs, Investigators and Research participants in a multinational HIV/AIDS study. AIDS Research and Human Retroviruses to appear 2006.

Mocroft A, Neaton J, Bebchuk J, Staszewski S, Antunes F, Knysz B, Law M, Phillips AN, Lundgren J. The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clinical Trials 2006; 206:119-132.

Bebchuk J, Betensky R. Tests for treatment differences in the hazards for survival before and after the occurrence of an intermediate event. Stat in Med 2005; 24:359-378.

Pace C, Grady C, Chuenyam T, Duncombe C, Bebchuk J, Wendler D, Tavel J, McNay L, Phanuphak P, Forster H, Emanuel E. The quality of informed consent in a clinical research study in Thailand. IRB Ethics and Human Research 2005; 27:9-17.

Markowitz N, Bebchuk J, Abrams D. Nadir CD4+ T-cell count predicts response to subcutaneous recombinant interleukin-2. Clinical Infectious Diseases 2003; 37:15-20.

McNay L, Tavel J, Oseekey K, McDermott C, Mollerup D, Bebchuk J. Regulatory approvals in a large multinational clinical trial: the ESPRIT experience. Controlled Clinical Trials 2002; 23:59-66.

Bebchuk J, Betensky R. Local likelihood analysis of the latency distribution with interval censored intermediate events. Stat in Med 2002; 21:3475-3491.

Abrams D, Bebchuk J, Denning E, et al. A randomized open-label study of the impact of two doses of subcutaneous recombinant IL-2 on viral burden in patients with HIV-1 infection and CD4+ Cell Counts 300/mm2: CPCRA 059, Journal of Acquired Immune Deficiency Syndromes (JAIDS), 2002; 29:221-231.

Bebchuk J, Betensky R. Local likelihood analysis of survival data with censored intermediate events. JASA 2001; 96:449-457.

Bebchuk J, Betensky R. Multiple imputation for simple estimation of the hazard function based on interval censored data. Stat in Med 2000; 19:405-419.

Horton N, Bebchuk J, Jones C, Lipsitz S, Catalano P, Fitzmaurice G. Goodness of fit for GEE: an example with mental health service utilization. Stat in Med 1999; 18:213-222.

Nader P, Sellers D, Johnson C, Perry C, Stone E, Cook K, Bebchuk J, Luepker R. The effect of adult participation in a school-based family intervention to improve children's diet and physical activity: the child and adolescent trial for cardiovascular health. Preventive Medicine 1996; 25:455-464.

McGraw S, Sellers D, Stone E., Bebchuk J, Edmundson E, Johnson C, Bachman, K, Luepker R. Using process data to explain outcomes. An illustration from the child and adolescent trial for cardiovascular health (CATCH). Evaluation Review 1996; 20:291-312.

Roberts J, Roos L, Poffenroth L, Hassard T, Bebchuk J, Carter A, Law B. Surveillance of vaccine-related adverse events in the first year of life: a Manitoba cohort study. Journal of Clinical Epidemiology 1996; 49:51-58.

Peterson E, Cowper P, Jollis J, Bebchuk J, DeLong E, Muhlbaier L, Mark D, Pryor D. Outcomes of coronary artery bypass graft surgery in 24,461 patients aged 80 years or older. Circulation 1995; 92(suppl):1185-91.

Peterson E, Jollis J, Bebchuk J, DeLong E, Muhlbaier L, Mark D, Pryor D. Changes in mortality after myocardial revascularization in the elderly. The national medicare experience. Annals of Internal Medicine 1994; 121:919-927.

Roberts J, Poffenroth L, Roos L, Bebchuk J, Carter A. Monitoring childhood immunizations: a Canadian approach. American Journal of Public Health 1994; 84:1666-1668.

Scherer K, Kraut A, Yassi A, Wajda A, Bebchuk J. Using administrative health data to monitor potential adverse health effects in environmental studies. Environmental Research 1994; 66:143-151.